Alnylam Pharmaceuticals, Inc. (BMV:ALNY)
Mexico · Delayed Price · Currency is MXN | Market Cap | 415.51B -64.2% |
| Revenue (ttm) | 90.36B +56.2% |
| Net Income | 47.75B +2,136.9% |
| EPS | 362.34 +2,056.9% |
| Shares Out | n/a |
| PE Ratio | 15.31 |
| Forward PE | 13.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42 |
| Open | 5,549.00 |
| Previous Close | 5,150.16 |
| Day's Range | 5,549.00 - 5,549.00 |
| 52-Week Range | 5,150.16 - 8,560.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
Alnylam price target lowered to $350 from $410 at Freedom Broker
Freedom Broker lowered the firm’s price target on Alnylam (ALNY) to $350 from $410 and keeps a Buy rating on the shares. The main change from the firm’s previous estimates…
Alnylam price target lowered to $240 from $300 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $240 from $300 and keeps an Equal Weight rating on the shares. In-line TTR sales were supported by one-time…
Alnylam price target lowered to $354 from $482 at TD Cowen
TD Cowen lowered the firm’s price target on Alnylam (ALNY) to $354 from $482 and keeps a Buy rating on the shares. The fim updated its model following inline Q3…
Alnylam price target lowered to $320 from $536 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Alnylam (ALNY) to $320 from $536 and keeps a Buy rating on the shares. Alnylam delivered an in-line Q3 but guided to…
Bernstein downgrades Alnylam to Market Perform, lowers target to $199
Bernstein downgraded Alnylam (ALNY) to Market Perform from Outperform with a price target of $199, down from $376, after the company stated their intention to refine TRITON-CM design to account…
Alnylam downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst William Pickering downgraded Alnylam (ALNY) to Market Perform from Outperform.
Alnylam price target lowered to $329 from $354 at UBS
UBS analyst Joon Lee lowered the firm’s price target on Alnylam (ALNY) to $329 from $354 and keeps a Buy rating on the shares. Alnylam’s outlook moderates near term, but…
Alnylam price target lowered to $320 from $350 at Oppenheimer
Oppenheimer lowered the firm’s price target on Alnylam (ALNY) to $320 from $350 and keeps an Outperform rating on the shares. The firm notes Alnylam was under pressure mainly due…
Alnylam price target lowered to $220 from $253 at Wells Fargo
Wells Fargo lowered the firm’s price target on Alnylam (ALNY) to $220 from $253 and keeps an Equal Weight rating on the shares. The firm doesn’t see investor Amvuttra growth…
Alnylam downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Martin Auster downgraded Alnylam (ALNY) to Outperform from Strong Buy with a price target of $315, down from $420, post the Q3 report. The firm cites limited…
Alnylam price target lowered to $375 from $425 at Chardan
Chardan analyst Keay Nakae lowered the firm’s price target on Alnylam (ALNY) to $375 from $425 and keeps a Buy rating on the shares following the Q3 report. The firm…
Alnylam: 340B rule change would ‘substantially reduce’ Medicare reimbursement
Alnylam (ALNY) said on its Q3 earnings call that the proposed CMS rule change that if finalized as proposed, would substantially reduce Medicare reimbursement for Part B medicines acquired through…
Alnylam selloff on payer restrictions overdone, says H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio attributes the post-earnings selloff in Alnylam (ALNY) to the quarterly filing highlighting Medicare Advantage step-therapy restrictions and potential disrupti...
Alnylam downgraded at Stifel on slowing growth, slower pipeline progress
As previously reported, Stifel downgraded Alnylam (ALNY) to Hold from Buy with a price target of $225, down from $318, following the company’s Q3 report. Near-term estimates for Amvuttra are…
Alnylam downgraded to Hold from Buy at Stifel
Stifel downgraded Alnylam (ALNY) to Hold from Buy with a price target of $225, down from $318.
Alnylam Phase 2 bleeding disorders data pushed out, says Jefferies
Jefferies notes that along with Q3 results, Alnylam (ALNY) issued “minor pipeline updates,” including a “slight push” to pipeline catalysts on bleeding and obesity. ALN-6400 for bleeding disorders Pha...
Alnylam sinks after delaying Phase 2 data release to 2027
Shares of Alnylam (ALNY) are moving lower after the company pushed out the timelines for its hereditary hemorrhagic telangiectasia data. Alnylam now expects to announce clinical data from the Phase…
Alnylam trading halted, volatility trading pause
09:35 EDT Alnylam (ALNY) trading halted, volatility trading pause
Alnylam Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 net product revenue rose 52% YoY to $1.29B, led by TTR, but AMVUTTRA demand growth lagged expectations. 2026 TTR sales are expected at the low end of guidance amid access and ordering uncertainty; TRITON-CM enrollment expanded and brezosiran advanced toward pivotal testing.
Alnylam Pharmaceuticals Earnings release: Q3 2026
Alnylam Pharmaceuticals released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Alnylam Pharmaceuticals Quarterly report: Q3 2026
Alnylam Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 29, 2026.
Alnylam Pharmaceuticals Slides: Q3 2026
Alnylam Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se...
Alnylam Pharmaceuticals Transcript: Investor update
Initial phase Ib data showed dose-dependent CSF HTT reductions of 60%-64% at month 3, with no reported dose-dependent signals in inflammation, neurofilament or ventricular volume. A pivotal placebo-controlled study is planned for 2027, pending regulatory alignment.